SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma - Quaterly Results

12 Aug 2023 Evaluate
The sales figure stood at Rs. 23908.20 millions for the June 2023 quarter. The mentioned figure indicates a growth of about 37.27% as compared to Rs. 17416.50 millions during the year-ago period.Net Profit for the quarter ended June 2023 zoomed to 134.22% from Rs. 1357.70 millions to Rs. 3180.00  millions.The company reported a good operating profit of 5172.60 millions compared to 2501.20 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 23908.20 17416.50 37.27 23908.20 17416.50 37.27 127922.80 112871.40 13.33
Other Income 948.80 378.80 150.48 948.80 378.80 150.48 4337.60 6709.90 -35.36
PBIDT 5172.60 2501.20 106.80 5172.60 2501.20 106.80 21646.80 21443.90 0.95
Interest 315.90 50.90 520.63 315.90 50.90 520.63 1149.80 169.40 578.75
PBDT 4856.70 2450.30 98.21 4856.70 2450.30 98.21 20497.00 20527.40 -0.15
Depreciation 596.30 560.10 6.46 596.30 560.10 6.46 4353.50 4152.60 4.84
PBT 4260.40 1890.20 125.39 4260.40 1890.20 125.39 16143.50 16374.80 -1.41
TAX 1080.40 532.50 102.89 1080.40 532.50 102.89 3839.40 1827.70 110.07
Deferred Tax -82.60 -99.90 -17.32 -82.60 -99.90 -17.32 -230.80 -1969.30 -88.28
PAT 3180.00 1357.70 134.22 3180.00 1357.70 134.22 12304.10 14547.10 -15.42
Equity 585.90 585.90 0.00 585.90 585.90 0.00 585.90 585.90 0.00
PBIDTM(%) 21.64 14.36 50.65 21.64 14.36 50.65 16.92 19.00 -10.93

Aurobindo Pharma Share Price

1372.00 -13.65 (-0.99%)
20-Apr-2026 12:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1238.75
Cipla 1240.00
Zydus Lifesciences 942.95
Lupin 2336.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×